Elm Biosciences
1 known investors
Elm Biosciences is a clinical skincare company that develops dermatologist-formulated anti-aging products built around its patent-pending A3O antioxidant complex, sold directly to consumers. Its line includes topical treatments and daily supplements aimed at reducing visible signs of skin aging.
Also known as Elm · Elm Bio
Founders & leadership
Investors · 1
Company profile
researched Aug 2026Elm Biosciences is a clinical skincare company that sells dermatologist-developed topical and ingestible products aimed at the visible signs of skin aging. Its catalogue includes the A3O Elemental Serum, the A3O Elemental Night Cream and the Inner Dose Daily Skin Supplement, along with multi-product bundles such as the A3O Complete Skin Renewal, the Dual Pathway Skin System, the Skin Longevity System and The Elemental Reset. Products are positioned around "skin longevity," targeting oxidative stress, environmental and UV-induced damage, inflammation and skin-barrier breakdown.
The brand is co-created by Martha Stewart, described on the company site as her first beauty brand, and by board-certified dermatologist Dr. Dhaval Bhanusali, who serves as co-founder and chief medical officer and leads development of the A3O Complex. The company states it works with an advisory community of more than 350 dermatologists, scientists and researchers, several of whom are named on its site with their practice locations across the United States, and describes a "farm to lab, lab to patient" model intended to move formulations from research directly to consumers.
Founding story
Elm was co-created by Martha Stewart and her dermatologist, Dr. Dhaval Bhanusali, with the stated aim of producing high-performance skincare formulas; it is described as Stewart's first beauty brand.
Business model
Direct-to-consumer sale of branded skincare and supplement products through the company's own e-commerce site, with individual SKUs priced from roughly $50 to $165 at regular price and discounted bundles offered at up to $350 regular price.
Product sales of topical skincare and daily ingestible supplements, sold individually and as multi-product bundles at discounted prices on the company website.
Latest developments
In early September 2025, Elm Biosciences was reported to have raised venture funding from Habitat Partners.
▸Full profile — market position, technology, go-to-market
Market position
Trade coverage places Elm Biosciences among companies entering the longevity skincare category alongside L'Oreal, OneSkin and Lancome.
The company differentiates on its proprietary, patent-pending A3O Complex, a stated lab-to-patient development model that brings formulations directly to consumers, and co-development with a network of more than 350 dermatologists and researchers.
Technology
The company's core asset is the patent-pending A3O Complex, described as a triple-pathway antioxidant and anti-senescence ingredient system intended to regulate inflammation and neutralize oxidative stress at the cellular level, and positioned as an alternative to Vitamin C without its irritation or instability. Formulations combine A3O with ingredients including hyaluronic acid, blue tansy, squalane, vitamin E, Polypodium leucotomos, organic turmeric, vitamin D3, astaxanthin and holy basil/tulsi, pairing topical products with ingestible adaptogen and micronutrient blends.
Go-to-market
Sold direct to consumers online, with positioning built on dermatologist development and endorsement, an advisory network of more than 350 dermatologists and scientists, and the co-founder profile of Martha Stewart.
Consumers seeking anti-aging and "skin longevity" skincare, including those with sensitive skin, reached directly rather than through clinical channels.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsElm Biosciences was listed among early stage venture transactions in the U.S. apparel, beauty and personal products sector for September 1-15, 2025, having raised venture funding from Habitat Partners. No amount was disclosed.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Elm Bioscienceselmbiosciences.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Elm Biosciences do?
- Elm Biosciences is a dermatologist-developed clinical skincare brand co-founded by Martha Stewart, built around its A3O complex.
- Who founded Elm Biosciences?
- Elm Biosciences was founded by Martha Stewart, Dhaval Bhanusali.
- Who are Elm Biosciences's investors?
- Elm Biosciences's investors include Habitat Partners.